People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Nerandomilast worked better than a placebo to preserve lung function in adults with progressive pulmonary fibrosis in a Phase ...

People in rural areas are at greater risk of developing chronic obstructive pulmonary disease (COPD) due to a variety of factors. We explain why.

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

This innovative program addresses global health initiatives and medical training in Peru with Partners in Health, known ...

In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB) at both the individual and population ...

SGLT-2 inhibitors and GLP-1 receptor agonists are linked to a reduced risk of COPD exacerbations in patients with type 2 ...

Recent findings suggest that post-COVID chronic cough may be driven by neurological factors, not just respiratory issues.

Columnist Caroline Gainer discusses a study whose findings suggested that respiratory muscle strength training could help ...